A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

INTRODUCTION: To determine the feasibility, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT) of pazopanib in combination with cisplatin. METHODS: Patients with advanced malignancies were included in a 3 + 3 dose-escalation phase I study. Pazopanib administration started 8 days before...

Descripción completa

Detalles Bibliográficos
Autores principales: Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315079/
https://www.ncbi.nlm.nih.gov/pubmed/28261651
http://dx.doi.org/10.1007/s40487-016-0027-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315079/
https://www.ncbi.nlm.nih.gov/pubmed/28261651
http://dx.doi.org/10.1007/s40487-016-0027-x

Ejemplares similares